<br> Content: Manufacture of core pellets by balling / Lucy S.C. Wan --<br/> Preparation of micropellets by spray congealing / A. Atilla Hincal, H. Suheyla Kas --<br/> Cryopelletization / Axel Knoch --<br/> Coating of multiparticulates using polymeric solutions: formulation and process consideration
Multiparticulate Drug Delivery: Formulation, Processing and Manufacturing
β Scribed by Ali R. Rajabi-Siahboomi (eds.)
- Publisher
- Springer-Verlag New York
- Year
- 2017
- Tongue
- English
- Leaves
- 402
- Series
- Advances in Delivery Science and Technology
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
Authored by leading experts from academia, users and manufacturers, this book provides an authoritative account of the science and technology involved in multiparticulate drug delivery systems which offer superior clinical and technical advantages over many other specialized approaches in drug delivery. The book will cover market trends, potential benefits and formulation challenges for various types of multiparticulate systems. Drug solubility, dose, chemistry and therapeutic indications as well as excipient suitability coupled with manufacturing methods will be fully covered. Key approaches for taste-masking, delayed release and extended release of multiparticulates systems are of significant interest, especially their in-vivo and in-vitro performance. In addition, the principles of scale-up, QbD, and regulatory aspects of common materials used in this technology will be explained, as well as recent advances in materials and equipment enabling robust, flexible and cost-effective manufacture. Case studies illustrating best practices will also make the book a valuable resource to pharmaceutical scientists in industry and academia.
β¦ Table of Contents
Front Matter....Pages i-xii
Overview of Multiparticulate Systems for Oral Drug Delivery....Pages 1-4
Characterization of Inert Cores for Multiparticulate Dosage Forms....Pages 5-35
The Science and Practice of Extrusion-Spheronization....Pages 37-63
Fluid Bed Technology, Process Robustness, and Scale-Up....Pages 65-93
Mini-tabs: Versatile Multiparticulate Option for Oral Drug Delivery....Pages 95-118
Science and Practice of Microencapsulation Technology....Pages 119-154
Multiparticulate Technologies for Fixed-Dose Combinations....Pages 155-168
Dissolution Test Considerations for Oral Multiparticulate Systems....Pages 169-212
Multiparticulate Systems for Paediatric Drug Delivery....Pages 213-236
Application of Poly(meth)acrylate Copolymers for Oral Multiparticulate Drug Delivery Systems....Pages 237-266
Ethylcellulose Applications in Multiparticulate Systems....Pages 267-299
In-Line Particle Size Characterization of Multiparticulate Systems....Pages 301-332
Filling of Hard Shell Capsules and Packaging Aspects of Multiparticulate Systems....Pages 333-357
In Vivo Characterization of Oral Multiparticulate Systems....Pages 359-386
Back Matter....Pages 387-396
β¦ Subjects
Pharmaceutical Sciences/Technology
π SIMILAR VOLUMES
Although multiparticulates, which comprise minitablets, pellets, and granules, have been taken by patients in one dosage form or another for quite some time, it is only in the last two decades that the full potential of multiparticulates as drug delivery systems has been realized in terms of both fl
Nanoparticles, products of nanotechnology, are of increasing interest to the pharmaceutical community. They can increase drug solubility, enhance bioavailability, allow tissue targeting, offer decreased side-effects, and improve therapeutic efficacy. Presenting the most pertinent and practical issue
In the past the ability to formulate topical creams and ointments has been described as both Β«artΒ» and Β«magic.Β» The demanding expectations of topicals include (1) formulations that have both chemical and physical stability for at least two years, (2) formulations that have components both alone and
<p>Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies<b> </b>discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA t